CClinicalTrials.gg
TerminatedNCT01122381Updated Aug 19, 2015Results posted

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

A Phase 1/2 interventional study of ethosuximide and placebo comparator in Headache, Migraine, sponsored by US Department of Veterans Affairs. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-08-19.

Sponsored by US Department of Veterans Affairs · Phase 1/2, Interventional, and Prevention

Why this study was terminated
poor recruitment
Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether ethosuximide works better than placebo in the prevention of episodic migraine among veterans.

Read the detailed description

Chronic and episodic headaches in veteran populations include migraine, transformed migraine, and post-traumatic headache with migrainous features. More and better prophylactic drugs with fewer side effects (such as weight gain) are needed to treat these disabling, refractory conditions which generally have less than a 50% response rate to preventative treatments.

Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and can be caused by mutations in a calcium channel gene. Serotonin is also known to be a critical neurotransmitter in migraine based on the pharmacology of acute and preventative treatments. We previously identified a "migraine" signaling pathway in an invertebrate C. elegans "hemiplegic migraine" model of a mutant calcium channel upstream from transforming growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX).

Objective: We propose to test our findings from this invertebrate migraine model to determine its relevance to humans in the prevention of episodic migraine.

Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2 randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week baseline.

02

Conditions studied

  • Headache, Migraine

Keywords

  • headache, migraine
  • depression
  • disability evaluation
  • weight gain
03

In context

Migraine Disorders

1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.

This study's enrollment of 5 is below the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

US Department of Veterans Affairs is the lead sponsor of 658 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Must be a veteran.
  • The number of migraine days per 4-week period is to be 4-14 for a period of 3 months prior to screening for entry into the trial.
  • Migraine must have been occurring for 6 months preceding entry into the trial and age of onset should be before age 60 years.
  • Migraine must be at least moderate severity and interrupt daily activities in some respect at least 3 times per month.
  • As long as the veteran can easily distinguish nonmigraine headaches from migraine, there is no limit on the number of non migraine headache days allowed. "Transformed migraine" headaches due to medication over usage will be excluded according to exclusion criteria #4.
  • Migraine diagnosis:

Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura.

Criteria for migraine without aura (I.H.S. 1.1)

  • > 5 attacks
  • headache lasting 4-72 hours when untreated or not successfully treated.
  • headache with two of the following characteristics

    • unilateral,
    • pulsating,
    • moderate to severe intensity,
    • aggravation by exertion.
  • one of the following occurs with headache

    • nausea and/or vomiting
    • photophobia and phonophobia

Criteria for migraine with aura (I.H.S. 1.2)

  • at least 2 attacks
  • at least three of the following characteristics:

    • One or more fully reversible aura symptoms indicating focal cerebral cortical - and/or brain stem dysfunction.

One or more aura symptoms of the following types:

  • Homonymous visual disturbance
  • Unilateral parenthesis and/or numbness
  • Unilateral weakness
  • Aphasia or unclassifiable speech difficulty

    • At least one aura symptom develops gradually over more than 4 minutes or, 2 or more symptoms occur in succession.
    • No aura symptom lasts more than 60 minutes. If more than one aura symptom is present, accepted duration is proportionally increased.
    • Headache follows aura with a free interval of less than 60 minutes. (It may also begin before or simultaneously with the aura). Headache, nausea and/or photophobia usually follow neurological aura symptoms directly or after a free interval of less than an hour. The headache usually lasts 4-72 hours, but may be completely absent (1.2.5, acephalgic migraine).

Exclusion criteria

Exclusion Criteria:

  • Veterans with migraine plus other systemic disorder will be excluded if migraine onset was temporally related to onset of the systemic disorder.
  • Blood pressure elevations (must be \< borderline values 135/85 for 4 weeks before enrollment into the study). Current treatment for hypertension with beta-blockers, calcium channel blockers, or ace inhibitors not allowed.
  • Use of other prophylactic migraine drugs (requires a washout phase) and cannot have failed more than two other prophylactic drugs for migraine.
  • Excessive use of acute pain medicines, including narcotics (>10 days month). Those using non-narcotics could be tapered off over 4-8 weeks.
  • Receiving disability or seeking disability for headache or chronic pain.
  • Significant neck pain or cervicogenic contributors to chronic headache.
  • Significant depression, anxiety, post-traumatic stress disorder, or other disabling psychiatric condition.
  • Known allergies or serious side effects with ESX or succinimides in the past.
  • Known liver or significant renal disease.
  • Women veterans of child-bearing age who do not have adequate birth control.
  • Chronic bone marrow suppression.
  • Using psychogenic or other sedating maintenance drugs.
  • History of porphyria.
  • History of cluster headache. 15.History of other CNS disease.
  • Age younger than 18 years and greater than 65.
  • Women veterans who are breastfeeding.
  • Veterans with familial hemiplegic migraine (FHM).

Ongoing exclusions during the study:

  • The addition of other migraine prophylactic headache medicines is not allowed. 2. New drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Arm 1-ethosuximide

    ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability

    Drug: ethosuximide

  • Placebo comparator
    Arm 2-placebo comparator

    placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability

    Other: placebo comparator

Interventions

  • Drugethosuximide

    ethosuximide (ESX)

    Also known as: zarontin

  • Otherplacebo comparator

    placebo

06

What researchers measure

Primary outcomes

  1. Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.

    Compare number of migraine headache days pre and post treatment between the ESX and placebo group. Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.

    Time frame: 4 weeks, end of treatment and pre-treatment baseline

07

Results

Posted Aug 19, 2015
Limitations and caveats
Early termination occurred due to inadequate recruitment of episodic migraineurs in a population meeting too many exclusion criteria; resulting in no subjects available for analysis.

Participant flow

Primary Care and Neurology Clinic prescreening and recruitment from VA Pittsburgh hospitals during the following periods: 1/14/11-4/1/11; 1/14/12-3/19/12; 2/4/13-3/12/14. Average prescreening of datawarehouse records for eligibility = 2954 subjects/month. Average prescreening electronic chart review for eligibility = 265 subjects/month.

Participant flow — Overall Study
MilestoneArm 1-drug TreatmentArm 2-placebo
Started11
Completed10
Not completed01
Withdrew: Study terminated early01

Outcome measures

PrimaryMigraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.

Compare number of migraine headache days pre and post treatment between the ESX and placebo group. Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.

Time frame:
4 weeks, end of treatment and pre-treatment baseline

No measurements were reported for this outcome.

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1- Ethosuximide—0/1 (0%)1/1 (100%)
Arm 2- Placebo Comparator—0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventArm 1- EthosuximideArm 2- Placebo Comparator
hiccupsRespiratory, thoracic and mediastinal disorders1/11/1
fatigueGeneral disorders1/11/1
diarrheaGastrointestinal disorders0/11/1
abdominal painGastrointestinal disorders1/10/1
somnolenceNervous system disorders1/10/1
nauseaGastrointestinal disorders0/11/1

Baseline characteristics

Enrollees who completed baseline period and randomization.

Age, Categorical
Age, Categorical(Participants)Arm 1Arm 2Total
<=18 years000
Between 18 and 65 years112
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1Arm 2Total
Female101
Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1Arm 2Total
Hispanic or Latino000
Not Hispanic or Latino112
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1Arm 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White112
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm 1Arm 2Total
United States112
08

Study locations

1 site
  • VA Pittsburgh Health Care System
    Pittsburgh, Pennsylvania 15240, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01122381
Lead sponsor
US Department of Veterans Affairs
Collaborators
Thomas Jefferson University, University of Pittsburgh
Responsible party
Sponsor
First posted
May 13, 2010
Start date
Dec 2011
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Aug 19, 2015
Last update
Aug 19, 2015

Study contacts

Kathy L Gardner, MD
principal investigator · VA Pittsburgh Health Care System

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion